Portal de investigación
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Airoldi M
- Puccini A
Grupos y Plataformas de I+D+i
Abstract
The treatment of locally advanced rectal cancer (LARC) has undergone a significant evolution in recent years, shifting toward more selective strategies that balance oncological outcomes with quality of life (QoL) preservation. Total neoadjuvant treatment (TNT) has improved local control and reduced distant metastases, but its long-term toxicities have sparked growing interest in treatment de-escalation strategies aimed at minimizing adverse effects while maintaining efficacy. This review focuses on the therapeutic advancements for LARC, analysing both established standards and emerging innovations. We discuss the increasing adoption of organpreserving approaches, particularly the Watch-and-Wait (WW) strategy for patients achieving a clinical complete response (cCR), and potentially the selective omission of radiotherapy in well-defined cases. Additionally, we explore and examine less invasive surgical techniques that preserve function without compromising cure rates. Beyond standard treatment approaches, we highlight the role of immunotherapy, particularly its breakthrough efficacy in LARC with deficient mismatch repair/microsatellite instability (dMMR/MSI), leading to the concept of immune-ablation: achieving complete tumor regression while sparing patients from chemotherapy, radiotherapy, and surgery. Ongoing research is investigating immunotherapy's potential role also in proficient mismatch repair/microsatellite stable (pMMR/MSS) LARC. Finally, we discuss emerging predictive biomarkers, such as circulating tumor DNA (ctDNA) and radiomics, which might refine patient selection and guide treatment individualization. The future of LARC management lies in a precision-driven approach, where survival is optimized without compromising QoL. By embracing innovation and personalizing care, we are entering a new era where cure remains paramount, but never at the expense of the patient's well-being.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0305-7372, 1532-1967
- Tipo:
- Review
- Páginas:
- 103015-103015
- PubMed:
- 40858040
CANCER TREATMENT REVIEWS ELSEVIER SCI LTD
Citas Recibidas en Web of Science: 3
Documentos
Filiaciones
Keywords
- Locally advanced rectal cancer; Total neoadjuvant treatment; Watch-and-wait; Organ preservation; Treatment de-escalation; Immunotherapy
Proyectos y Estudios Clínicos
Caracterización y abordaje de la enfermedad mínima residual en cáncer de colon localizado: un paso hacia la medicina de precisión.
Investigador/a Principal NOELIA TARAZONA LLAVERO
PI21/00689 . INSTITUTO SALUD CARLOS III . 2022
Enfoque integral de la enfermedad micrometastásica hepática en cáncer colorrectal: caracterización multiómica de metástasis, respuesta inmune y abordaje de la enfermedad residual.
Investigador/a Principal NOELIA TARAZONA LLAVERO
PI24/00103 . INSTITUTO SALUD CARLOS III . 2025
Cita
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life. Airoldi,M, Roselló,S, Tarazona,N, Huerta,M, Pérez Santiago,L, Fleitas,T, Pla Martí,V et al. CANCER TREATMENT REVIEWS. 2025 noviembre 01. 140103015-103015. DOI:10.1016/j.ctrv.2025.103015. PMID:40858040.
